Articles

Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. More

Investors should look at these three undervalued sleeper stocks in December to boost and fortify their financial portfolios. More

Over the last several months, solar stocks lost their shine. But most are coming back strong as we head into 2024. More

After the S&P 500 becomes this overbought for the first time in a year, stocks tend to pull back – then soar over the next 12 and 24 months. More

ACN stock results show that Accenture beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. More

Micromobility.com is about to be delisted from the Nasdaq. It's time to ditch MCOM stock before the stock disappears. More

The widely followed investors has scored home runs in 2023 with these securities, each of which has bounced back over the past year. More

Subscriber Sign in